{"id":1527,"date":"2022-04-17T12:57:00","date_gmt":"2022-04-17T12:57:00","guid":{"rendered":"https:\/\/johannessiebert.com\/?p=1527"},"modified":"2022-12-12T08:26:06","modified_gmt":"2022-12-12T08:26:06","slug":"methode-zur-unterstutzung-der-innovation-bei-entscheidungen-in-der-fruhen-phase-der-pharmazeutischen-entwicklung","status":"publish","type":"post","link":"https:\/\/johannessiebert.com\/?p=1527","title":{"rendered":"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions"},"content":{"rendered":"\n

Pharmazeutische Unternehmen \u00fcberpr\u00fcfen ihr Portfolio regelm\u00e4\u00dfig, um den Entwicklungsfortschritt zu \u00fcberwachen und Priorit\u00e4ten bei der Entwicklung von Produkten zu setzen. Bei den fr\u00fchesten Verm\u00f6genswerten handelt es sich um Arzneimittelkandidaten, deren Wirksamkeit unbekannt ist und deren Auswirkungen auf den menschlichen K\u00f6rper noch nicht vollst\u00e4ndig erforscht sind. Bei diesen Verm\u00f6genswerten ist es sehr unsicher, ob sie den Markt erreichen und in der klinischen Praxis eingesetzt werden. Dar\u00fcber hinaus sind nicht alle potenziellen Anwendungen vorhersehbar und k\u00f6nnen oft sehr unterschiedlich sein. In Ermangelung zufriedenstellender Methoden f\u00fcr die Entscheidung \u00fcber die Zuteilung von Ressourcen f\u00fcr fr\u00fche Entwicklungsg\u00fcter konzentrieren sich die Entscheidungstr\u00e4ger fast ausschlie\u00dflich auf die Bewertung der Wahrscheinlichkeit des technischen Erfolgs eines Gutes.<\/p>\n\n\n\n

In dieser Studie wird eine ganzheitlichere Methodik zur Unterst\u00fctzung von Entscheidungen in der fr\u00fchen Phase der pharmazeutischen Entwicklung vorgeschlagen, bei der Value-focused Thinking und multikriterielle Entscheidungsfindung zum Einsatz kommen. Die Methodik funktioniert innerhalb des Rahmens f\u00fcr die Entscheidungsqualit\u00e4t und bietet eine konsistente Bewertung verschiedener fr\u00fcher Entwicklungsg\u00fcter in einer Vielzahl von Krankheitsbereichen. Diese Kombination von Konzepten und Methoden wurde bei Bayer Pharmaceuticals implementiert und hat sich dort als n\u00fctzlich erwiesen, da das Unternehmen einen neuen, robusteren Entscheidungsfindungsprozess f\u00fcr die fr\u00fche Entwicklung ben\u00f6tigte. In dieser Studie wird daher er\u00f6rtert, wie konkrete Abw\u00e4gungen auf der Ebene der Unternehmensziele m\u00f6glich sind, um die Unternehmensstrategie auf die Portfoliostrategie abzustimmen, zu kommunizieren und umzusetzen.<\/p>\n\n\n\n

Dar\u00fcber hinaus werden in dieser Studie Erkenntnisse f\u00fcr Entscheidungsanalysten und Entscheidungstr\u00e4ger in der pharmazeutischen Industrie vorgestellt, wie man eine Reihe grundlegender Ziele entwickelt, wie man Skalen zur Operationalisierung dieser Ziele erstellt und wie man Schritte zur Entlastung eines organisatorischen Entscheidungsprozesses unternimmt.<\/p>\n\n\n\n

Methling, Florian; Borden, Steffen A., Veeraraghavan, Deepak; Sommer; Insa, Siebert, Johannes Ulrich; von Nitzsch, R\u00fcdiger; Seidler, Mark \u201eSupporting Innovation in Early-Stage Pharmaceutical Development Decisions \u201c, in Special Issue on Health Decision Analysis: Evolution, Trends, and Emerging Topics by Elisa F. Long, Gilberto Montibeller, Jun Zhuang, Decision Analysis<\/em> (INFORMS), https:\/\/doi.org\/10.1287\/deca.2022.0452 <\/a><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Pharmazeutische Unternehmen \u00fcberpr\u00fcfen ihr Portfolio regelm\u00e4\u00dfig, um den Entwicklungsfortschritt zu \u00fcberwachen und Priorit\u00e4ten bei der Entwicklung von Produkten zu setzen. Bei den fr\u00fchesten Verm\u00f6genswerten handelt es sich um Arzneimittelkandidaten, deren Wirksamkeit unbekannt ist und deren Auswirkungen auf den menschlichen K\u00f6rper noch nicht vollst\u00e4ndig erforscht sind. Bei diesen Verm\u00f6genswerten ist es sehr unsicher, ob sie den […]<\/p>\n","protected":false},"author":1,"featured_media":1033,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[91],"tags":[],"class_list":["post-1527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-veroeffentlichungen-forschung"],"yoast_head":"\nSupporting Innovation in Early-Stage Pharmaceutical Development Decisions - Johannes Siebert<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johannessiebert.com\/?p=1527\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions - Johannes Siebert\" \/>\n<meta property=\"og:description\" content=\"Pharmazeutische Unternehmen \u00fcberpr\u00fcfen ihr Portfolio regelm\u00e4\u00dfig, um den Entwicklungsfortschritt zu \u00fcberwachen und Priorit\u00e4ten bei der Entwicklung von Produkten zu setzen. Bei den fr\u00fchesten Verm\u00f6genswerten handelt es sich um Arzneimittelkandidaten, deren Wirksamkeit unbekannt ist und deren Auswirkungen auf den menschlichen K\u00f6rper noch nicht vollst\u00e4ndig erforscht sind. Bei diesen Verm\u00f6genswerten ist es sehr unsicher, ob sie den […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johannessiebert.com\/?p=1527\" \/>\n<meta property=\"og:site_name\" content=\"Johannes Siebert\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-17T12:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-12T08:26:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/05\/Decision-Analysis.png\" \/>\n\t<meta property=\"og:image:width\" content=\"179\" \/>\n\t<meta property=\"og:image:height\" content=\"239\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/#\\\/schema\\\/person\\\/88a0e8f3ff381564ff3156e66b6ef3bc\"},\"headline\":\"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions\",\"datePublished\":\"2022-04-17T12:57:00+00:00\",\"dateModified\":\"2022-12-12T08:26:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/#\\\/schema\\\/person\\\/88a0e8f3ff381564ff3156e66b6ef3bc\"},\"image\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Decision-Analysis.png\",\"articleSection\":[\"ver\u00f6ffentlichungen-forschung\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527\",\"url\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527\",\"name\":\"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions - Johannes Siebert\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Decision-Analysis.png\",\"datePublished\":\"2022-04-17T12:57:00+00:00\",\"dateModified\":\"2022-12-12T08:26:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johannessiebert.com\\\/?p=1527\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#primaryimage\",\"url\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Decision-Analysis.png\",\"contentUrl\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Decision-Analysis.png\",\"width\":179,\"height\":239},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/?p=1527#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johannessiebert.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/#website\",\"url\":\"https:\\\/\\\/johannessiebert.com\\\/\",\"name\":\"Johannes Siebert\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/#\\\/schema\\\/person\\\/88a0e8f3ff381564ff3156e66b6ef3bc\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johannessiebert.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/#\\\/schema\\\/person\\\/88a0e8f3ff381564ff3156e66b6ef3bc\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/168-Qualitaet-von-Entscheidungen-1.bmp\",\"url\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/168-Qualitaet-von-Entscheidungen-1.bmp\",\"contentUrl\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/168-Qualitaet-von-Entscheidungen-1.bmp\",\"width\":650,\"height\":738,\"caption\":\"admin\"},\"logo\":{\"@id\":\"https:\\\/\\\/johannessiebert.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/168-Qualitaet-von-Entscheidungen-1.bmp\"},\"url\":\"https:\\\/\\\/johannessiebert.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions - Johannes Siebert","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johannessiebert.com\/?p=1527","og_locale":"en_US","og_type":"article","og_title":"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions - Johannes Siebert","og_description":"Pharmazeutische Unternehmen \u00fcberpr\u00fcfen ihr Portfolio regelm\u00e4\u00dfig, um den Entwicklungsfortschritt zu \u00fcberwachen und Priorit\u00e4ten bei der Entwicklung von Produkten zu setzen. Bei den fr\u00fchesten Verm\u00f6genswerten handelt es sich um Arzneimittelkandidaten, deren Wirksamkeit unbekannt ist und deren Auswirkungen auf den menschlichen K\u00f6rper noch nicht vollst\u00e4ndig erforscht sind. Bei diesen Verm\u00f6genswerten ist es sehr unsicher, ob sie den […]","og_url":"https:\/\/johannessiebert.com\/?p=1527","og_site_name":"Johannes Siebert","article_published_time":"2022-04-17T12:57:00+00:00","article_modified_time":"2022-12-12T08:26:06+00:00","og_image":[{"width":179,"height":239,"url":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/05\/Decision-Analysis.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johannessiebert.com\/?p=1527#article","isPartOf":{"@id":"https:\/\/johannessiebert.com\/?p=1527"},"author":{"name":"admin","@id":"https:\/\/johannessiebert.com\/#\/schema\/person\/88a0e8f3ff381564ff3156e66b6ef3bc"},"headline":"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions","datePublished":"2022-04-17T12:57:00+00:00","dateModified":"2022-12-12T08:26:06+00:00","mainEntityOfPage":{"@id":"https:\/\/johannessiebert.com\/?p=1527"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/johannessiebert.com\/#\/schema\/person\/88a0e8f3ff381564ff3156e66b6ef3bc"},"image":{"@id":"https:\/\/johannessiebert.com\/?p=1527#primaryimage"},"thumbnailUrl":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/05\/Decision-Analysis.png","articleSection":["ver\u00f6ffentlichungen-forschung"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/johannessiebert.com\/?p=1527#respond"]}]},{"@type":"WebPage","@id":"https:\/\/johannessiebert.com\/?p=1527","url":"https:\/\/johannessiebert.com\/?p=1527","name":"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions - Johannes Siebert","isPartOf":{"@id":"https:\/\/johannessiebert.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johannessiebert.com\/?p=1527#primaryimage"},"image":{"@id":"https:\/\/johannessiebert.com\/?p=1527#primaryimage"},"thumbnailUrl":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/05\/Decision-Analysis.png","datePublished":"2022-04-17T12:57:00+00:00","dateModified":"2022-12-12T08:26:06+00:00","breadcrumb":{"@id":"https:\/\/johannessiebert.com\/?p=1527#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johannessiebert.com\/?p=1527"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johannessiebert.com\/?p=1527#primaryimage","url":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/05\/Decision-Analysis.png","contentUrl":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/05\/Decision-Analysis.png","width":179,"height":239},{"@type":"BreadcrumbList","@id":"https:\/\/johannessiebert.com\/?p=1527#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johannessiebert.com\/"},{"@type":"ListItem","position":2,"name":"Supporting Innovation in Early-Stage Pharmaceutical Development Decisions"}]},{"@type":"WebSite","@id":"https:\/\/johannessiebert.com\/#website","url":"https:\/\/johannessiebert.com\/","name":"Johannes Siebert","description":"","publisher":{"@id":"https:\/\/johannessiebert.com\/#\/schema\/person\/88a0e8f3ff381564ff3156e66b6ef3bc"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johannessiebert.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johannessiebert.com\/#\/schema\/person\/88a0e8f3ff381564ff3156e66b6ef3bc","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/04\/168-Qualitaet-von-Entscheidungen-1.bmp","url":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/04\/168-Qualitaet-von-Entscheidungen-1.bmp","contentUrl":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/04\/168-Qualitaet-von-Entscheidungen-1.bmp","width":650,"height":738,"caption":"admin"},"logo":{"@id":"https:\/\/johannessiebert.com\/wp-content\/uploads\/2021\/04\/168-Qualitaet-von-Entscheidungen-1.bmp"},"url":"https:\/\/johannessiebert.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/posts\/1527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1527"}],"version-history":[{"count":5,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/posts\/1527\/revisions"}],"predecessor-version":[{"id":1567,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/posts\/1527\/revisions\/1567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=\/wp\/v2\/media\/1033"}],"wp:attachment":[{"href":"https:\/\/johannessiebert.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johannessiebert.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}